University of Giessen

Hamlet BioPharma's Phase II Trial Shows Immunotherapy Matches Antibiotics for Cystitis

8 months ago

• Hamlet BioPharma's Phase II trial demonstrates that anakinra immunotherapy achieves similar clinical outcomes to antibiotics in treating recurrent acute cystitis. • The study showed significant symptom reduction, fewer recurrences, and improved quality of life for patients treated with both anakinra and antibiotics. • This research supports immunotherapy as a potential alternative to antibiotics, addressing the growing threat of antibiotic resistance in urinary tract infections. • The findings suggest that immunomodulatory approaches targeting IL-1 may offer a non-antibiotic strategy for managing recurrent acute cystitis.

End-of-Dose Phenomena Observed in Multiple Sclerosis Patients on Ofatumumab

8 months ago

• A study of 103 MS patients found that 34% experienced end-of-dose phenomena (EOD) with ofatumumab, impacting their quality of life. • EOD was associated with higher baseline disability, longer disease duration, and older age, highlighting the need for careful monitoring. • Fatigue, cognitive impairment, and gait difficulties were the most commonly reported EOD symptoms among patients on ofatumumab. • Compared to ocrelizumab, ofatumumab showed a lower incidence of the wearing-off effect in a separate study, suggesting potential differences in B-cell depletion.